Carol Giltner Gallagher
CIK 1329959 · SVP, Corp Dev & Comm Affairs · last filed 2026-06-05
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$4.64M
Companies
9
Total Filings
52
Lifetime Open-Market Net
-$1.99M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PMVP | Director | — | $1.11 | — | $0 | 5 | 2026-06-05 |
| ATRA | Director | 95,668 | $10.41 | $995.9K | -$1.99M | 30 | 2025-06-12 |
| Mirati Therapeutics, Inc. (MRTX) Delisted | Director | 6,808 | $58.70 | $399.6K | $0 | 3 | 2024-01-23 |
| Frazier Lifesciences Acquisition Corp (FLACW) Delisted | Director | — | $0.80 | — | $0 | 1 | 2022-11-23 |
| Turning Point Therapeutics, Inc. (TPTX) Delisted | Director | — | $76.01 | — | $0 | 4 | 2022-08-17 |
| CERT | Director | 7,059 | $5.20 | $36.7K | $0 | 1 | 2021-06-16 |
| Tempest Therapeutics, Inc. (MLND) Delisted | Director | 31,933 | $15.90 | $507.7K | $0 | 4 | 2020-06-23 |
| ANAB | Director | 64,296 | $56.07 | $3.61M | $0 | 3 | 2018-02-06 |
| ANADYS PHARMACEUTICALS INC (ANDS) Delisted | SVP, Corp Dev & Comm Affairs | — | — | — | $0 | 1 | 2007-05-18 |
Recent Filings · Page 3 of 6
52 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-06-17 | Turning Point Therapeutics, Inc. (TPTX) Delisted | Mixed | — | $0 | EDGAR |
| 2019-07-25 | Turning Point Therapeutics, Inc. (TPTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-07-01 | ATRA | Grant (A) | +4,000 | $0 | EDGAR |
| 2019-06-21 | Tempest Therapeutics, Inc. (MLND) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-01-17 | Tempest Therapeutics, Inc. (MLND) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-12-11 | Tempest Therapeutics, Inc. (MLND) Delisted | Grant (A) | +31,933 | $0 | EDGAR |
| 2018-11-07 | ATRA | Sell (S) | −21,374 | -$777.6K | EDGAR |
| 2018-06-19 | ATRA | Sell (S) | −2,500 | -$111.9K | EDGAR |
| 2018-06-18 | ATRA | Grant (A) | +1,500 | $0 | EDGAR |
| 2018-05-16 | ATRA | Mixed | +272 | -$12.6K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.